Advanced Drug Delivery Systems for Colonic Disorders

Dr. Harish Dureja is Professor and Head, Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak. Dr. Dureja is also the Director, Centre for IPR Studies and Director, Professional Consultancy Cell. Dr. Dureja has more than 22 years of teaching experience. He also holds 18 years research experience in the field of nanoparticulate drug delivery, regulatory affairs and in silico ADME modeling. Dr. Dureja has been awarded with Gold-Medal for the best Ph.D. thesis and research projects worth 1.2 Crore from various funding agencies. He has filed an Indian patent and written a book and authored more than twenty five book chapters. He has published 265 publications in various international and national journals of repute. He worked as Chairman-Scientific Services Committee (LOC) during 69th IPC at Chitkara University, Raj-pura. He also worked as content writer for e-Pathashala program of Ministry of Human Resources Development for Post Graduate course of Pharmaceutical Sciences for the paper novel drug delivery system. He has delivered more than 180 invited Lectures in various conferences, seminars and symposiums and has guided 60 PG scholars and 10 students for doctoral work. He has been awarded the Gold-Medal for Best Ph.D. Thesis, Best Paper Award - Prof. M.L. Khorana Memorial Prize Award – 2005 and Dr. R.L. Nicore award - 2018. He has published six special issues as a Guest Editor for the Journals published by Bentham Science Publishers, and one issue published by Frontiers, Switzerland. He is currently also serving as President, Association of Pharmaceutical Teachers of India (APTI), Haryana State Branch. Prof Raimar Löbenberg holds a BS in Pharmacy from the Johannes Gutenberg-University, Germany. He received his PhD in Pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt in 1996 for his work on drug delivery using nanoparticles. He joined the University of Alberta in 2000, where he is now a Professor in Pharmaceutical Sciences. His research interests are inhalable nanoparticles to treat lung diseases such as lung cancer and tuberculosis. His lab regularly develops and characterises nanoparticles for various inflammatory diseases and cancer. His lab also hosts a unique pencentury device which assists in effectively delivering nanoparticles to the lungs of rodents. He holds a US patent for the delivery of nanoparticles to the lungs. Another major interest area is Biopharmaceutics, and predicting the oral performance of drugs and botanicals. Prof Löbenberg is a founder and Director of the Drug Development and Innovation Centre at the University of Alberta. The Centre specialises in clinical trial material production, and holds a Health Canada site licence and a drug establishment licence. The Centre has controlled substance licences to synthesise psychedelics in a dedicated chemistry lab. The quality control lab has state-of-the-art analytical instruments and other pharmaceutically relevant performance test instruments. Prof Löbenberg is a former president of the Canadian Society for Pharmaceutical Sciences (2014-2015). He is a member and Vice Chair of the United States Pharmacopeia Dietary Supplement Expert Committee, a Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science, and a member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology, and of the Health Canada Scientific Advisory Committee on Opiate Abuse. Dr. Sachin Kumar Singh, is working as professor and head of Pharmaceutical Chemistry and Pharmaceutical Analysis at School of Pharmaceutical Sciences, Lovely Professional University, India and visiting professor Australian Research Centre in Complementary and Integrative Medicine (ARCCIM), School of Public Health, Faculty of Health, University of Technology Sydney, Australia. He has many years of teaching and research experience. Dr. Singh has published more than 350 research papers with cumulative impact of 1300, authored several books, and dozens of book chapters. He is also featured under top 2% scientists of world as per the list of 2021, published by Stanford University, USA. Muralikrishnan Dhanasekaran, is a Professor of Pharmacology and Toxicology at the Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University. He earned his Ph.D. in 1999 from the Jadavpur University, India, in neuropharmacology. From 1999-2001, he became a post-doctoral fellow at the University of Nebraska Medical Center, Omaha, Nebraska, and the Uni-versity of North Dakota School of Medicine and Health Sciences, Grand Forks, ND. He served as a re-search instructor of pharmacology at Texas A & M Health Sciences, Temple, TX. His major area of teaching and research is related to pathophysiology, pharmacology, and toxicology in dementia, movement disorders, addiction (substances of abuse-designer drugs, nicotine, alcohol), hyperglycemia, epilepsy, and aging. His research was funded by the Alzheimer’s Association and Pharmaceutical com-panies in the USA. He has over one hundred and thirteen peer-reviewed publications, fifty book chap-ters, and around four hundred abstracts in national and international meetings in the area of pharma-cology, toxicology, and natural bioactives. He has received several awards for teaching, service, and outreach. He has been an editor or on the editorial board for several books and journals including nat-ural products, pharmacology, toxicology, and neuropharmacology. Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over many years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.

1. Introduction to colonic disorders Manvi Singh, Puru Goel, Mayank Phagna, Reena Badhwar, Zeenat Iqbal and Mohd. Aamir Mirza 2. Cellular and molecular mechanisms involved in colonic disorders Simranjit Kaur, Arshdeep Singh, Harpreet Kaur, Jagbir Singh and Rajbir Bhatti 3. Current approaches for treatment of colonic disorder Manish Gupta, Priya Sen, Mahendra Saini, Mahaveer Singh, Pawan Bagiyal, Pramod Kumar and Gaurav Gupta 4. Polysaccharides based drug delivery systems for the treatment of colon diseases Sadaf Arfi, Nimisha Srivastava and Deepti Dwivedi 5. Synthetic polymers as biomaterials for the treatment of colon diseases Sundeep Chaurasia and Brahmeshwar Mishra 6. Mucoadhesive polymers as biomaterials for the treatment of colon disorders Nitesh Kumar, Priyanka Verma, Varun Kumar, Rachel Kaul and Surbhi Mishra 7. Colon-responsive oral drug delivery for combating colonic disorders Anindita Behera 8. Colon-responsive targeted drug delivery for treating colonic disorder Anil K. Philip, Bassim I. Mohammad and Hayder A. Al-Aubaidy 9. Advancement in targeted drug delivery systems in managing colonic disorders C. Sarath Chandran, Krishnameera Sajayan, Jeeva C. Soman, P.K. Anjana, K.K. Swathy, A.S. Vishnu and Shijina Kappally 10. Nutraceuticals and phytoceuticals in the treatment of colonic disorders Nitin Verma, Jatin Kumar, Neha Kanojia, Komal Thapa and Kamal Dua 11. Role of Prebiotics, Probiotics and synbiotics in the management of colonic disorders Faizan Naeem Razali, Wuen Yew Teoh, Muhammad Zaki Ramli, Ching-Yee Loo and Charles Gnanaraj 12. Era of biotics in managing colonic disorders Shvetank Bhatt, K. Anitha, Sujit Kumar Sah, Nishant Prasad Apte, Sakina. Mullamitha and Jamila Chechatwala 13. Innovations in liposomal drug delivery: paving the way for personalized cancer therapy Alaa A.A. Aljabali, Mohammad A. Obeid, Mohamed El-Tanani and Murtaza M. Tambuwala 14. Nanoparticulate drug delivery systems for colonic disorders Girish Kumar, Tarun Virmani, Ashwani Sharma, Reshu Virmani and Kamla Pathak 15. 3D printing-assisted colon-targeted drug delivery systems Chandrakantsing Pardeshi, Ganesh Shevalkar, Mahesh Umbarkar, Dipak Bari, Kamalesh Mali, Sameer Lakade and Monica Garcıa 16. Radiopharmaceutical-based approaches for the determination of colon-targeting efficiency Akshita Arora, Anshul Sharma, Richa Kumari and Nitin Sharma 17. Colonic disorder management: challenges an prospects Alan Raj, M. Sonal Sekhar and Angel Treasa Alex 18. Clinical trials and regulatory aspects of drug delivery system for colonic disorders Riya Shivgotra, Manjot Kaur, Shubham Thakur, Bindu Soni, Hossamaldeen Bakrey and Subheet Kumar Jain